Glaxo takes £1.6bn Genome bid fully hostile
Britain's biggest drugs firm, GlaxoSmithKline, yesterday stormed ahead with its $2.6bn (£1.6bn) hostile takeover of United States biotech Human Genome Sciences, waving aside the board to take its bid direct to shareholders.
Glaxo is Human Genome's major partner, working together on Benlysta, the first new lupus drug approved in the US in half a century.
But the biotech last month rejected GSK's $13-a-share cash offer, which was more than 80 per cent higher than its unaffected closing share price, saying the bid price did "not reflect the value" of HGS.
The US firm instead hired Goldman Sachs and Credit Suisse to launch a strategic review, which included considering putting itself up for sale. Yesterday, however, GSK showed it wasn't prepared to wait and took its bid direct to investors, saying its offer was "full and fair".
The drugmaker, headed by Sir Andrew Witty added: "GSK's participation in the [review] process is unnecessary as its offer is not conditioned on due diligence or financing and can be completed expeditiously. It is important for HGS shareholders to understand that GSK is committed to proceeding with its offer.
"There is clear strategic and financial logic to this combination and HGS shareholders should have the opportunity to decide for themselves on the merits of the offer."
Glaxo is being advisedby Lazard and Morgan Stanley.
- 1 Stem cells that can kill cancer have been engineered by scientists
- 2 Ricky Gervais and Dame Judi Dench back campaign to stop Thailand dog meat trade
- 3 Russell Brand says he will 'probably' give up acting to focus on his revolution
- 4 Kentucky gang rape: 15-year-old boy left in critical condition after sexual attack by group at party
- 5 Queen's first tweet: Reply telling Her Majesty to 'f*** off' broadcast on BBC News
Stem cells that can kill cancer have been engineered by scientists
Ottawa shooting: 'Sergeant-at-arms shot suspect at point-blank range after diving around pillar'
Russell Brand says he will 'probably' give up acting to focus on his revolution
McKamey Manor: This 'extreme' haunted house is the stuff of nightmares
Jack Bruce dead: Cream bass player dies of liver disease aged 71
Of course, teenage girls need role models – but not like beauty vlogger Zoella
Support for EU membership 'at highest level since 1991' with most Brits wanting to stay 'in'
Tony Blair 'says Ed Miliband will lose 2015 general election'
Thousands with degenerative conditions classified as 'fit to work in future' – despite no possibility of improvement
Putin: The US is to blame for almost all the world's major conflicts
Attacks on 'Ukip Calypso' show how skewed people’s priorities are
iJobs Money & Business
£60000 per annum: Ashdown Group: Compensation and Benefits Manager - Compensat...
£30000 - £35000 Per Annum plus excellent benefits: Clearwater People Solutions...
£24000 - £28000 per annum + bonus & benefits: Ashdown Group: IT Business Syste...
£50000 - £90000 per annum + benefits: Ampersand Consulting LLP: Markit EDM (CA...